Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SPVN20
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Recipient : SparingVision
Deal Size : Undisclosed
Deal Type : Divestment
SparingVision Sells Ex Vivo GIRK Technology to Tenpoint Therapeutics
Details : Through the divestment, Tenpoint has acquired SparingVision's ex vivo GIRK technology. SparingVision will remain focused on in vivo genomic medicines, with SPVN20, a GIRK-based gene therapy candidate.
Brand Name : SPVN20
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
July 12, 2023
Lead Product(s) : SPVN20
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Recipient : SparingVision
Deal Size : Undisclosed
Deal Type : Divestment
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : Discovery Platform
Sponsor : British Patient Capital
Deal Size : $70.0 million
Deal Type : Series A Financing
Details : Tenpoint will use the net proceeds to develop its regenerative medicine platform to replace multiple cell types lost to inherited and age-related conditions.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
July 12, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Discovery Platform
Sponsor : British Patient Capital
Deal Size : $70.0 million
Deal Type : Series A Financing
LOOKING FOR A SUPPLIER?
Reset All
